Literature DB >> 22407976

Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain.

Juan Carlos Almagro1, Gopalan Raghunathan, Eric Beil, Dariusz J Janecki, Qiang Chen, Thai Dinh, Ann LaCombe, Judy Connor, Mark Ware, Paul H Kim, Ronald V Swanson, Johan Fransson.   

Abstract

Disulfide bridges are common in the antigen-binding site from sharks (new antigen receptor) and camels (single variable heavy-chain domain, VHH), in which they confer both structural diversity and domain stability. In human antibodies, cysteine residues in the third complementarity-determining region of the heavy chain (CDR-H3) are rare but naturally encoded in the IGHD germline genes. Here, by panning a phage display library designed based on human germline genes and synthetic CDR-H3 regions against a human cytokine, we identified an antibody (M3) containing two cysteine residues in the CDR-H3. It binds the cytokine with high affinity (0.4 nM), recognizes a unique epitope on the antigen, and has a distinct neutralization profile as compared with all other antibodies selected from the library. The two cysteine residues form a disulfide bridge as determined by mass spectrometric peptide mapping. Replacing the cysteines with alanines did not change the solubility and stability of the monoclonal antibody, but binding to the antigen was significantly impaired. Three-dimensional modeling and dynamic simulations were employed to explore how the disulfide bridge influences the conformation of CDR-H3 and binding to the antigen. On the basis of these results, we envision that designing human combinatorial antibody libraries to contain intra-CDR or inter-CDR disulfide bridges could lead to identification of human antibodies with unique binding profiles.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22407976     DOI: 10.1002/jmr.1168

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  14 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

Review 2.  Phage display--a powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

3.  An ultra-specific avian antibody to phosphorylated tau protein reveals a unique mechanism for phosphoepitope recognition.

Authors:  Heather H Shih; Chao Tu; Wei Cao; Anne Klein; Renee Ramsey; Brian J Fennell; Matthew Lambert; Deirdre Ní Shúilleabháin; Bénédicte Autin; Eugenia Kouranova; Sri Laxmanan; Steven Braithwaite; Leeying Wu; Mostafa Ait-Zahra; Anthony J Milici; Jo Ann Dumin; Edward R LaVallie; Maya Arai; Christopher Corcoran; Janet E Paulsen; Davinder Gill; Orla Cunningham; Joel Bard; Lydia Mosyak; William J J Finlay
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

4.  Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus.

Authors:  Peter S Lee; Nobuko Ohshima; Robyn L Stanfield; Wenli Yu; Yoshitaka Iba; Yoshinobu Okuno; Yoshikazu Kurosawa; Ian A Wilson
Journal:  Nat Commun       Date:  2014-04-10       Impact factor: 14.919

5.  Reshaping antibody diversity.

Authors:  Feng Wang; Damian C Ekiert; Insha Ahmad; Wenli Yu; Yong Zhang; Omar Bazirgan; Ali Torkamani; Terje Raudsepp; Waithaka Mwangi; Michael F Criscitiello; Ian A Wilson; Peter G Schultz; Vaughn V Smider
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

6.  Hepatitis C virus E2 envelope glycoprotein core structure.

Authors:  Leopold Kong; Erick Giang; Travis Nieusma; Rameshwar U Kadam; Kristin E Cogburn; Yuanzi Hua; Xiaoping Dai; Robyn L Stanfield; Dennis R Burton; Andrew B Ward; Ian A Wilson; Mansun Law
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

7.  Reconciling the structural attributes of avian antibodies.

Authors:  Paul J Conroy; Ruby H P Law; Sarah Gilgunn; Stephen Hearty; Tom T Caradoc-Davies; Gordon Lloyd; Richard J O'Kennedy; James C Whisstock
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

8.  Formylbenzene diazonium hexafluorophosphate reagent for tyrosine-selective modification of proteins and the introduction of a bioorthogonal aldehyde.

Authors:  Julia Gavrilyuk; Hitoshi Ban; Masanobu Nagano; Wataru Hakamata; Carlos F Barbas
Journal:  Bioconjug Chem       Date:  2012-11-29       Impact factor: 4.774

9.  Natural and man-made V-gene repertoires for antibody discovery.

Authors:  William J J Finlay; Juan C Almagro
Journal:  Front Immunol       Date:  2012-11-15       Impact factor: 7.561

10.  Discovering neutralizing antibodies targeting the stem epitope of H1N1 influenza hemagglutinin with synthetic phage-displayed antibody libraries.

Authors:  Chao-Ping Tung; Ing-Chien Chen; Chung-Ming Yu; Hung-Pin Peng; Jhih-Wei Jian; Shiou-Hwa Ma; Yu-Ching Lee; Jia-Tsrong Jan; An-Suei Yang
Journal:  Sci Rep       Date:  2015-10-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.